Sanofi India Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
6054.65 -26.50 (-0.44%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6025
Today’s High
6130
52 Week Low
4382.64
52 Week High
7593.6
6054.05 -22.65 (-0.37%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6009.05
Today’s High
6146.95
52 Week Low
4694.05
52 Week High
7600
Key Metrics
- Market Cap (In Cr) 13995.02
- Beta 0.62
- Div. Yield (%) 1.93
- P/B 13.79
- TTM P/E 45.08
- Peg Ratio 3.77
- Sector P/E 32.87
- D/E -
- Open Price 6031.5
- Prev Close 6081.15
Sanofi India Analysis
Price Analysis
-
1 Week-5.18%
-
3 Months-11.41%
-
6 Month8.76%
-
YTD20.43%
-
1 Year23.58%
Risk Meter
- 82% Low risk
- 82% Moderate risk
- 82% Balanced Risk
- 82% High risk
- 82% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 2
- 2
- 2
- 2
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 3
- 3
- 3
- 3
Sanofi India News
Glenmark, JB Pharma, Ajanta, Zydus, Sanofi lead Indian Pharma Market growth
2 min read . 14 Jun 2024Sanofi India, Semac Consultants & others hit 52 week low today ;Check the full list here?
4 min read . 13 Jun 2024Sanofi India Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2023
- Total Revenue
- 2851.1
- Selling/ General/ Admin Expenses Total
- 818.4
- Depreciation/ Amortization
- 39.6
- Other Operating Expenses Total
- -0.2
- Total Operating Expense
- 2090.8
- Operating Income
- 760.3
- Net Income Before Taxes
- 845.5
- Net Income
- 602.9
- Diluted Normalized EPS
- 257.01
- Period
- 2023
- Total Assets
- 1714.8
- Total Liabilities
- 699.6
- Total Equity
- 1015.2
- Tangible Book Valueper Share Common Eq
- 437.55
- Period
- 2023
- Cashfrom Operating Activities
- 230.4
- Cashfrom Investing Activities
- 37.5
- Cashfrom Financing Activities
- -878.3
- Net Changein Cash
- -610.4
- Period
- 2022
- Total Revenue
- 2770.1
- Selling/ General/ Admin Expenses Total
- 850.2
- Depreciation/ Amortization
- 41.9
- Other Operating Expenses Total
- -0.2
- Total Operating Expense
- 1989.1
- Operating Income
- 781
- Net Income Before Taxes
- 864.3
- Net Income
- 620.6
- Diluted Normalized EPS
- 229.28
- Period
- 2022
- Total Assets
- 2071.7
- Total Liabilities
- 795.9
- Total Equity
- 1275.8
- Tangible Book Valueper Share Common Eq
- 551.74
- Period
- 2022
- Cashfrom Operating Activities
- 398.7
- Cashfrom Investing Activities
- 650.9
- Cashfrom Financing Activities
- -1582.7
- Net Changein Cash
- -533.1
- Period
- 2021
- Total Revenue
- 2956.6
- Selling/ General/ Admin Expenses Total
- 862.8
- Depreciation/ Amortization
- 66.7
- Other Operating Expenses Total
- -0.1
- Total Operating Expense
- 1771.5
- Operating Income
- 1185.1
- Net Income Before Taxes
- 1257.6
- Net Income
- 944.4
- Diluted Normalized EPS
- 248.4
- Period
- 2021
- Total Assets
- 3061
- Total Liabilities
- 835.4
- Total Equity
- 2225.6
- Tangible Book Valueper Share Common Eq
- 964.11
- Period
- 2021
- Cashfrom Operating Activities
- 558.8
- Cashfrom Investing Activities
- 630.8
- Cashfrom Financing Activities
- -849
- Net Changein Cash
- 340.6
- Period
- 2020
- Total Revenue
- 2901.9
- Selling/ General/ Admin Expenses Total
- 894.4
- Depreciation/ Amortization
- 82.2
- Other Operating Expenses Total
- -0.1
- Total Operating Expense
- 2309.8
- Operating Income
- 592.1
- Net Income Before Taxes
- 677.2
- Net Income
- 477.6
- Diluted Normalized EPS
- 221
- Period
- 2020
- Total Assets
- 2918.5
- Total Liabilities
- 799.5
- Total Equity
- 2119
- Tangible Book Valueper Share Common Eq
- 871.8
- Period
- 2020
- Cashfrom Operating Activities
- 611.1
- Cashfrom Investing Activities
- 276.4
- Cashfrom Financing Activities
- -810
- Net Changein Cash
- 77.5
- Period
- 2019
- Total Revenue
- 3070.6
- Selling/ General/ Admin Expenses Total
- 992
- Depreciation/ Amortization
- 99.9
- Other Operating Expenses Total
- -0.3
- Total Operating Expense
- 2562.3
- Operating Income
- 508.3
- Net Income Before Taxes
- 599.9
- Net Income
- 414.2
- Diluted Normalized EPS
- 198.2
- Period
- 2019
- Total Assets
- 3244.4
- Total Liabilities
- 802.1
- Total Equity
- 2442.3
- Tangible Book Valueper Share Common Eq
- 995.02
- Period
- 2019
- Cashfrom Operating Activities
- 412.3
- Cashfrom Investing Activities
- 65.7
- Cashfrom Financing Activities
- -183.2
- Net Changein Cash
- 294.8
- Period
- 2018
- Total Revenue
- 2770.8
- Selling/ General/ Admin Expenses Total
- 914.9
- Depreciation/ Amortization
- 102.7
- Other Operating Expenses Total
- 22.8
- Total Operating Expense
- 2248.1
- Operating Income
- 522.7
- Net Income Before Taxes
- 609.8
- Net Income
- 380.6
- Diluted Normalized EPS
- 165.75
- Period
- 2018
- Total Assets
- 2983.9
- Total Liabilities
- 764.7
- Total Equity
- 2219.2
- Tangible Book Valueper Share Common Eq
- 881.26
- Period
- 2018
- Cashfrom Operating Activities
- 373.9
- Cashfrom Investing Activities
- -73.1
- Cashfrom Financing Activities
- -197.2
- Net Changein Cash
- 103.6
- Period
- 2024-09-30
- Total Revenue
- 524
- Selling/ General/ Admin Expenses Total
- 56.7
- Depreciation/ Amortization
- 9
- Other Operating Expenses Total
- 87.6
- Total Operating Expense
- 413.3
- Operating Income
- 110.7
- Net Income Before Taxes
- 112.6
- Net Income
- 82.2
- Diluted Normalized EPS
- 35.69
- Period
- 2024-09-30
- Period
- 2024-09-30
- Period
- 2024-06-30
- Total Revenue
- 463.5
- Selling/ General/ Admin Expenses Total
- 60.2
- Depreciation/ Amortization
- 9
- Other Operating Expenses Total
- 66.5
- Total Operating Expense
- 356.8
- Operating Income
- 106.7
- Net Income Before Taxes
- 92.1
- Net Income
- 103.2
- Diluted Normalized EPS
- 35.72
- Period
- 2024-06-30
- Total Assets
- 1360.3
- Total Liabilities
- 675.7
- Total Equity
- 684.6
- Tangible Book Valueper Share Common Eq
- 296.56
- Period
- 2024-06-30
- Cashfrom Operating Activities
- 254.1
- Cashfrom Investing Activities
- -12.1
- Cashfrom Financing Activities
- -388.3
- Net Changein Cash
- -146.3
- Period
- 2024-03-31
- Total Revenue
- 732.4
- Selling/ General/ Admin Expenses Total
- 92.4
- Depreciation/ Amortization
- 10
- Other Operating Expenses Total
- 112.7
- Total Operating Expense
- 523.5
- Operating Income
- 208.9
- Net Income Before Taxes
- 188.4
- Net Income
- 136.6
- Diluted Normalized EPS
- 67.72
- Period
- 2024-03-31
- Period
- 2024-03-31
- Period
- 2023-12-31
- Total Revenue
- 693.9
- Selling/ General/ Admin Expenses Total
- 91.9
- Depreciation/ Amortization
- 10.2
- Other Operating Expenses Total
- 134.3
- Total Operating Expense
- 516.7
- Operating Income
- 177.2
- Net Income Before Taxes
- 188.8
- Net Income
- 137.7
- Diluted Normalized EPS
- 59.79
- Period
- 2023-12-31
- Total Assets
- 1714.8
- Total Liabilities
- 699.6
- Total Equity
- 1015.2
- Tangible Book Valueper Share Common Eq
- 437.55
- Period
- 2023-12-31
- Cashfrom Operating Activities
- 230.4
- Cashfrom Investing Activities
- 37.5
- Cashfrom Financing Activities
- -878.3
- Net Changein Cash
- -610.4
- Period
- 2023-09-30
- Total Revenue
- 714.6
- Selling/ General/ Admin Expenses Total
- 93.2
- Depreciation/ Amortization
- 9.9
- Other Operating Expenses Total
- 113.4
- Total Operating Expense
- 516.3
- Operating Income
- 198.3
- Net Income Before Taxes
- 209.8
- Net Income
- 151.9
- Diluted Normalized EPS
- 65.95
- Period
- 2023-09-30
- Period
- 2023-09-30
- Period
- 2023-06-30
- Total Revenue
- 706.1
- Selling/ General/ Admin Expenses Total
- 93.7
- Depreciation/ Amortization
- 9.8
- Other Operating Expenses Total
- 117.9
- Total Operating Expense
- 537.7
- Operating Income
- 168.4
- Net Income Before Taxes
- 183.4
- Net Income
- 122.9
- Diluted Normalized EPS
- 53.37
- Period
- 2023-06-30
- Total Assets
- 1497.6
- Total Liabilities
- 773.4
- Total Equity
- 724.2
- Tangible Book Valueper Share Common Eq
- 311.45
- Period
- 2023-06-30
- Cashfrom Operating Activities
- 259.3
- Cashfrom Investing Activities
- 43.4
- Cashfrom Financing Activities
- -873.5
- Net Changein Cash
- -570.8
- Period
- 2023-03-31
- Total Revenue
- 736.5
- Selling/ General/ Admin Expenses Total
- 91.8
- Depreciation/ Amortization
- 9.7
- Other Operating Expenses Total
- 110.2
- Total Operating Expense
- 516.3
- Operating Income
- 220.2
- Net Income Before Taxes
- 263.5
- Net Income
- 190.4
- Diluted Normalized EPS
- 77.09
- Period
- 2023-03-31
- Period
- 2023-03-31
- Period
- 2022-12-31
- Total Revenue
- 671.9
- Selling/ General/ Admin Expenses Total
- 103.6
- Depreciation/ Amortization
- 10
- Other Operating Expenses Total
- 120.3
- Total Operating Expense
- 501.1
- Operating Income
- 170.8
- Net Income Before Taxes
- 190.4
- Net Income
- 130.9
- Diluted Normalized EPS
- 52.69
- Period
- 2022-12-31
- Total Assets
- 2071.7
- Total Liabilities
- 795.9
- Total Equity
- 1275.8
- Tangible Book Valueper Share Common Eq
- 551.74
- Period
- 2022-12-31
- Cashfrom Operating Activities
- 398.7
- Cashfrom Investing Activities
- 650.9
- Cashfrom Financing Activities
- -1582.7
- Net Changein Cash
- -533.1
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Sanofi India Technical
Moving Average
SMA
- 5 Day6162.9
- 10 Day6317.68
- 20 Day6447.41
- 50 Day6779.6
- 100 Day6715.82
- 300 Day7562.31
Sanofi India Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Jubilant Pharmova
- 1142.85
- 12
- 1.06
- 1309
- 408.6
- 18097.11
- Caplin Point Laboratories
- 1962
- 18.5
- 0.95
- 2175
- 1179.95
- 14899.77
- Sanofi India
- 6054.65
- -26.5
- -0.44
- 7593.6
- 4382.64
- 13944.23
- Marksans Pharma
- 307.35
- -1.65
- -0.53
- 328.35
- 126.05
- 13927.99
- Granules India
- 558.3
- 12.85
- 2.36
- 724.55
- 359.85
- 13531.45
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Jubilant Pharmova
- 120.43
- 3.29
- 6.15
- 5.13
- Caplin Point Laboratories
- 32.55
- 6.4
- 22.81
- 25.39
- Sanofi India
- 23.92
- 13.95
- 31.61
- 21.03
- Marksans Pharma
- 42.46
- 6.7
- 19.36
- 14.03
- Granules India
- 32.91
- 4.15
- 18.62
- 11.82
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 07-Nov-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 13-May-24
- Quarterly Results
- 23-Feb-24
- Audited Results & Dividend
- 08-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 10-May-23
- Quarterly Results
- 23-Feb-23
- Audited Results & Dividend
- 03-Nov-22
- Quarterly Results
- 26-Jul-22
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 10-Aug-24
- 11-Jul-24
- POM
- 14-May-24
- 22-Apr-24
- AGM
- 15-Feb-24
- 12-Jan-24
- POM
- 18-Dec-23
- 13-Nov-23
- COM
- 07-Nov-23
- 03-Oct-23
- POM
- 11-May-23
- 23-Feb-23
- AGM
- 24-Jun-22
- 28-Apr-22
- POM
- 26-Apr-22
- 23-Feb-22
- AGM
- 25-Mar-22
- 15-Feb-22
- POM
- 27-Apr-21
- 23-Feb-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 24-Feb-24
- 03-May-24
- 03-May-24
- 117
- 23-Feb-24
- 07-Mar-24
- 07-Mar-24
- 50
- 23-Feb-23
- -
- 28-Apr-23
- 194
- 24-Feb-23
- -
- 28-Apr-23
- 183
- 13-Jul-22
- 08-Aug-22
- 05-Aug-22
- 0
- 13-Jul-22
- 08-Aug-22
- 05-Aug-22
- 193
- 24-Feb-22
- -
- 12-Apr-22
- 309
- 23-Feb-22
- -
- 12-Apr-22
- 181
- 23-Feb-21
- -
- 19-Apr-21
- 125
- 24-Feb-21
- -
- 19-Apr-21
- 240